(Q34729698)

4 August 2017

title

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum (English)

1 reference

low-grade serous carcinoma

4 August 2017

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

0 references

5

Anais Malpica

1 reference

4 August 2017

1

Kathleen M Schmeler

1 reference

4 August 2017

7

Pedro T Ramirez

1 reference

4 August 2017

8

David M Gershenson

1 reference

4 August 2017

Charlotte C Sun

2

1 reference

4 August 2017

Diane C Bodurka

series ordinal

3

1 reference

4 August 2017

Michael T Deavers

series ordinal

4

1 reference

4 August 2017

Robert L Coleman

series ordinal

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

26 December 2007

1 reference

4 August 2017

1 reference

4 August 2017

volume

108

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

510-514

1 reference

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Observer variation in histologic classification of malignant and borderline ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Histopathologic grading of ovarian carcinoma: a review and proposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

A new histologic grading index in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2007.11.013

1 reference

4 August 2017

1 reference